UPB

Upstream Bio, Inc. UPB

NasdaqSmall CapHealthcare

13F Pro quality score

Rank #2,690 of 2,925

Why it scores 23Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$773.0K

Quarter to Jun 30

Net income

$-39.70M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$349.85M total
FMR LLC
$56.49M+0.8%
ORBIMED ADVISORS LLC
$39.40M0.0%
NORGES BANK
$26.08M--
BlackRock, Inc.
$25.97M+11.4%
Decheng Capital LLC
$18.86M0.0%
Enavate Sciences GP, LLC
$17.02M0.0%
VANGUARD CAPITAL MANAGEMENT LLC
$12.99M+0.2%
MILLENNIUM MANAGEMENT LLC
$7.91M+22.0%
D. E. Shaw & Co., Inc.
$7.17M+26.3%
JPMORGAN CHASE & CO
$7.01M+118.6%
Qube Research & Technologies Ltd
$6.77M+58.0%
Parkman Healthcare Partners LLC
$6.47M+18.9%
GEODE CAPITAL MANAGEMENT, LLC
$6.45M-2.0%
SEB Asset Management AB
$6.08M0.0%
Woodline Partners LP
$5.75M0.0%
STATE STREET CORP
$5.30M+8.6%
VANGUARD PORTFOLIO MANAGEMENT LLC
$4.93M-2.1%
Y-Intercept (Hong Kong) Ltd
$4.80M-30.7%
Bain Capital Life Sciences Investors, LLC
$4.16M-30.7%
AQR CAPITAL MANAGEMENT LLC
$3.77M+655.0%
MORGAN STANLEY
$3.63M-5.1%
BNP PARIBAS FINANCIAL MARKETS
$3.54M+306.0%
Walleye Capital LLC
$3.45MNew
Trexquant Investment LP
$3.23M+164.0%
Point72 Asset Management, L.P.
$3.13M+154.3%
See all 150 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/UPB

Earnings Per Share

13fpro.ai/company/UPB

Loading ratio trend…

UPB key financials by period

Reported revenue, net income and operating margin by fiscal year, from Upstream Bio, Inc.'s annual filings on SEC EDGAR.

Upstream Bio, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$2.9M$-143.4M—
FY 2024$2.4M$-62.8M—
FY 2023$2.4M$-20.5M—
Source: UPB filings on SEC EDGAR →

Companies similar to UPB

Ranked by quality-factor profile and overlapping institutional ownership, from the latest 13F filings and SEC financials.

UPB insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Upstream Bio, Inc. (UPB): stock profile, AI score and financials

Upstream Bio, Inc. (UPB) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores UPB at 23.2/100 on a composite quality score built from its SEC filings, placing it at rank #2,690 of 2,925 stocks — the bottom half of the AI-ranked universe. UPB scores in the top quartile across institutional flow (89.7), revenue growth (79.7). Areas of concern include free cash flow (0.9) and profitability (1.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 1.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Upstream Bio, Inc. reports quarterly revenue of $773.0K, net income of $-39.7M. UPB trades on the Nasdaq exchange and files with the SEC under CIK 2022626. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate UPB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Upstream Bio, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 2022626 →